Skip to main content

Table 1 Baseline demographics, disease characteristics and comorbidities (analysis population)

From: Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study

Characteristic

N = 865

Demographics

Age

N = 865

  Mean (SD), years

56.5 (12.1)

  <65 years, n (%)

615 (71.1)

  ≥65 years, n (%)

250 (28.9)

Body mass indexa

N = 818

  Mean (SD), kg/m2

27.5 (5.8)

  <25 kg/m2, n (%)

310 (37.9)

  25– < 30 kg/m2, n (%)

275 (33.6)

  30– < 35 kg/m2, n (%)

154 (18.8)

  ≥35 kg/m2, n (%)

79 (9.7)

Sex

N = 865

  Men, n (%)

146 (16.9)

  Women, n (%)

719 (83.1)

Country

N = 865

  Canada, n (%)

163 (18.8)

  Germany, n (%)

370 (42.8)

  Greece, n (%)

110 (12.7)

  Italy, n (%)

222 (25.7)

Disease characteristics

RA duration

N = 842

  Mean (SD), years

11.4 (8.7)

  ≤2 years, n (%)

83 (9.9)

  3–5 years, n (%)

169 (20.1)

  6–10 years, n (%)

224 (26.6)

  >10 years, n (%)

366 (43.5)

Tender joint count/28

N = 848

  Mean (SD)

11.4 (7.3)

Swollen joint count/28

N = 858

  Mean (SD)

7.9 (5.9)

HAQ-DI

N = 796

  <1.50, n (%)

332 (41.7)

  ≥1.50, n (%)

464 (58.3)

DAS28 (ESR, otherwise CRP)

N = 793

  Remission or LDAS (≤3.2), n (%)

24 (3.0)

  MDAS (>3.2–5.1), n (%)

203 (25.6)

  HDAS (>5.1), n (%)

440 (55.5)

  Not done, n (%)

126 (15.9)

CDAI (calculated)

N = 865

  Remission, LDAS, or MDAS (≤22), n (%)

196 (22.7)

  HDAS (>22), n (%)

568 (65.7)

  Missing, n (%)

101 (11.7)

Radiographic erosion (presence)

N = 750

  No, n (%)

218 (29.1)

  Yes, n (%)

532 (70.9)

CRP

N = 865

  <4 mg/L, n (%)

224 (25.9)

  4– < 10 mg/L, n (%)

172 (19.9)

  10– < 26 mg/L, n (%)

204 (23.6)

  ≥26 mg/L, n (%)

182 (21.0)

  Not done, n (%)

83 (9.6)

RF status

N = 852

  Negative, n (%)

225 (26.4)

  Positive, n (%)

494 (58.0)

  Not available, n (%)

133 (15.6)

Anti-CCP status

N = 834

  Negative, n (%)

162 (19.4)

  Positive, n (%)

294 (35.3)

  Not available, n (%)

378 (45.3)

Comorbidities

Cardiovascular disorders

N = 865

  No, n (%)

807 (93.3)

  Yes, n (%)

58 (6.7)

  Cardiac arrhythmia, n (%)

22 (2.5)

  Cardiac valve disorder, n (%)

9 (1.0)

  Coronary artery disorder, n (%)

23 (2.7)

  Heart failure, n (%)

15 (1.7)

  Myocardial disorder, n (%)

2 (0.2)

COPD

N = 865

  No, n (%)

803 (92.8)

  Yes, n (%)

62 (7.2)

Diabetes mellitus

N = 865

  No, n (%)

753 (87.1)

  Yes, n (%)

112 (12.9)

Tobacco use

N = 865

  No, n (%)

757 (87.5)

  Yes, n (%)

108 (12.5)

Infections and infestations

N = 865

  No, n (%)

809 (93.5)

  Yes, n (%)

56 (6.5)

  1. Category in italics is the reference for univariate and multivariate analyses
  2. The analysis population included patients treated in Canada, Germany, Greece, and Italy who had received at least one prior biologic agent and had a baseline clinical assessment no later than 8 days after the first administration of abatacept
  3. CCP cyclic citrullinated peptide, CDAI Clinical Disease Activity Index, CRP C-reactive protein, DAS Disease Activity Score, ESR erythrocyte sedimentation rate, HAQ-DI Health Assessment Questionnaire-Disability Index, HDAS high Disease Activity Score, LDAS low Disease Activity Score, MDAS moderate Disease Activity Score, RA rheumatoid arthritis, RF rheumatoid factor, SD standard deviation
  4. aWorld Health Organization body mass index classification: underweight/normal if <25 kg/m2, overweight if 25– < 30 kg/m2, obese class I if 30– < 35 kg/m2, and obese class II/III if ≥35 kg/m2 [21]
Back to article page

BMC Musculoskeletal Disorders

ISSN: 1471-2474

Contact us